Dongfang Baitai has been approved to establish a postdoctoral research workstation.
[Summary Description]
Recently, with the approval of the Ministry of Human Resources and Social Security and the National Postdoctoral Administration Committee, Beijing Dongfang Baitai Biotechnology Co., Ltd. has successfully established a postdoctoral research workstation. This initiative aims to further cultivate and attract high-caliber scientific and technological talent, bolster the company’s intensive R&D efforts, and mark a new milestone in the enterprise’s research capabilities.
Recently, with the approval of the Ministry of Human Resources and Social Security and the National Postdoctoral Administration Committee, Beijing Dongfang Baitai Biotechnology Co., Ltd. has successfully established a postdoctoral research workstation. This initiative aims to further cultivate and attract high-caliber scientific and technological talent, bolster the company’s intensive R&D efforts, and mark a new milestone in the enterprise’s research capabilities.

What is a postdoctoral research workstation?
A postdoctoral research workstation is an organization—established within enterprises, research‑production institutions, or specialized regional entities—that has been approved to recruit and train postdoctoral researchers. The establishment of such workstations aims to attract, cultivate, and employ high‑level young talent, particularly innovative and outstanding individuals; to create flexible mechanisms that facilitate talent mobility; and to promote scientific research, technological development, and the commercialization of research outcomes. By bridging China’s high‑tech talent with industry, these workstations represent a new approach to integrating industry, academia, and research.
The Significance of Postdoctoral Research Workstations
The establishment of postdoctoral research workstations helps to leverage the postdoctoral system’s role in identifying and cultivating outstanding scientific talent. It enables enterprises to broadly recruit highly qualified doctoral researchers with strong technical expertise and robust research‑practice capabilities, encouraging promising, innovative postdocs to undertake cutting‑edge research. This, in turn, facilitates the in-depth advancement of R&D projects, accelerates the translation of scientific and technological achievements into real‑world productivity, and plays a vital role in fostering independent innovation and enhancing core competitiveness. The initiative is highly forward‑looking, innovative, and exemplary, while also marking a new stage in the enterprise’s research endeavors and signaling a further提升 in its level of innovation.

Oriental Baitai Postdoctoral Research Station
Beijing Dongfang Baitai Biotechnology Co., Ltd. is located in the Beijing Economic-Technological Development Area, covering a total site area of nearly 60,000 square meters. It is a high-tech enterprise primarily focused on the research, development, and industrialization of innovative biopharmaceutical products for the treatment and prevention of major diseases. The company fully meets the national requirements for establishing postdoctoral research workstations and urgently seeks to set up such a station to attract more top-tier talent to its antibody‑drug R&D efforts, thereby helping to alleviate the challenges Chinese patients face in accessing affordable medications.

I. Personnel Team:
Orient Baitai has consistently prioritized the cultivation of innovative, research‑driven talent. After several years of development, the company now boasts a core R&D team composed of seasoned experts with extensive industry experience and a well‑balanced mix of specialized skills. With a total workforce of over 100 employees, including 14 PhDs and 47 master’s degree holders—accounting for more than half of the staff—and with over 80% of the team dedicated to R&D, the company has established a solid foundation for sustainable, innovation‑driven growth.
II. Honors and Qualifications:
The company has repeatedly received recognition and support from the national government and local authorities at all levels. It has been designated by the Ministry of Science and Technology as a “National International Science and Technology Cooperation Base for Cutting-Edge Technologies in Novel Antibodies and Therapeutic Protein Drugs,” and it hosts Beijing’s first batch of antibody engineering–related municipal engineering laboratories, the Beijing Engineering Research Center for Antibody Drugs, the Beijing Engineering Technology Research Center for Genetic Engineering Antibody Drugs, and the Beijing International Cooperation Base for Novel Antibodies and Therapeutic Proteins. Furthermore, it is a “G20 Reserve” enterprise. Recently, the Beijing Association for Science and Technology awarded it the designation of the “Oriental Baitai Academician and Expert Workstation,” underscoring its leading position in antibody drug research and development.
III. Status of Undertaking National Projects:
Oriental Baitai has successively undertaken numerous national “863” projects, key provincial and ministerial‑level science and technology programs, as well as other major government‑funded research initiatives under the 12th and 13th Five‑Year Plans. These include seven national major new‑drug development projects, three international collaborative projects, and more than ten R&D breakthrough programs sponsored by the Beijing Municipal Science & Technology Commission, the National Development and Reform Commission, and the Beijing Municipal Commission of Economy and Information Technology. Following the outbreaks of Ebola and Zika, Oriental Baitai was entrusted with developing relevant antibody therapeutics as part of China’s mechanism for the joint prevention and control of major infectious diseases. This not only underscores the company’s strong technical capabilities but also highlights its significant contributions to the advancement of the biopharmaceutical industry.
IV. Status of Ongoing Project Research and Development:
Status of the company’s ongoing R&D projects: The company has established a pipeline of more than 20 R&D programs targeting major diseases such as cancer, diabetes, and autoimmune disorders, and has obtained five clinical trial approvals for new drugs. The pipeline covers a broad range of prevalent conditions, including malignant tumors, rheumatoid arthritis, hyperlipidemia, and diabetes; product categories encompass fully human monoclonal antibodies, humanized monoclonal antibodies, bispecific antibodies, antibody–fusion proteins, antibody–drug conjugates, and therapeutic vaccines.
The company places great emphasis on the research and development of cutting-edge technologies and holds dozens of core invention patents. The type II diabetes drug JY09 has been granted patents in China, the United States, Europe, Japan, South Korea, and Eurasia; its patents for tumor immunotherapy have entered the international PCT phase. The launch of any one of these products would represent a blockbuster‑level breakthrough in the biopharmaceutical field.
V. R&D Platform:
Oriental Baitai has established an industry‑leading, end‑to‑end R&D‑production platform centered on innovative antibody therapeutics and next‑generation vaccines, seamlessly integrating antibody discovery with the entire manufacturing process. This includes:
1) High-capacity antibody library construction platform
2) High-throughput innovative antibody screening platform
3) Antibody–drug conjugate (ADC) coupling platform
4) Bispecific antibody construction platform
5) Therapeutic Vaccine Development Platform
6) Screening of mammalian cell lines with high expression levels
7) Process Optimization Platform
8) Pilot-scale production platform
9) Quality Control Platform
10) Pharmacodynamics and Toxicology Platform
11) Large-scale industrialization platform.
VI. Pilot Production Line:
The existing pilot‑scale production facility covers approximately 800 square meters and is a GMP‑compliant pilot line, comprising an upstream cell‑culture section and a downstream protein‑purification section. The cell‑culture pilot line focuses on the development and scale‑up of suspension mammalian cell‑culture processes and is extensively utilized for pilot‑scale production of antibody proteins and for providing clinical‑sample manufacturing services.
VII. Production Line:
Currently, the company is constructing a new antibody R&D and manufacturing facility, which includes one 3,000-liter mammalian cell bioreactor for large-scale batch cultivation and purification, as well as one bacterial/yeast production line, among other R&D infrastructure.
Future Workstation Planning
Dongfang Baitai places great emphasis on the establishment and management of its postdoctoral research workstation, steadfastly pursuing a development path that integrates industry, academia, and research. Moving forward, the company will proactively consolidate internal resources, assign responsibilities clearly, and establish an organizational management system that operates smoothly and coordinates efficiently. In line with the company’s R&D strategy, research priorities, and practical needs for talent cultivation and deployment, it will meticulously formulate medium- and long-term plans for the workstation’s development. Taking into account the unique characteristics of postdoctoral work, the company will refine and institutionalize routine administrative procedures, promote standardization in postdoctoral operations, and provide incoming postdocs with the necessary resources and facilities to support their research.
The Dongfang Baitai Postdoctoral Research Station collaborates with renowned domestic universities and research institutes’ postdoctoral stations to jointly cultivate a cohort of high-caliber professionals. We are now publicly recruiting postdoctoral researchers for 2018 and warmly welcome doctoral graduates in relevant fields to join us!
May we seize together the historic opportunities presented by the industrialization of the biopharmaceutical sector, focus on advancing innovative technologies in monoclonal antibody therapeutics, and contribute our part to making cutting-edge antibody‑based therapies accessible to patients in China and around the world!
Previous page
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message